Competitive Assay Patents (Class 435/7.93)
  • Patent number: 10368544
    Abstract: A reactive antibacterial compound is represented by formula (I) or (II): wherein R1 represents OCN-L-NHCOOR?, OCN-L-NHCONHR?, OCN-L-NHCOSR?, OCN-L-COOR?, or OCN-L-COONHR?. G1 represents OCN-M-NHCOOG?, OCN-M-NHCONHG?, OCN-M-NHCOSG?, OCN-M-COOG?, or OCN-M-COONHG?. L, M, R? and G? independently for each occurrence represent divalent alkyl and cycloalkyl having from 1 to 18 carbon atoms, optionally substituted by up to 18 heteroatoms. R4 and G4 independently for each occurrence represent a divalent alkyl and cycloalkyl having from 1 to 18 carbon atoms, optionally substituted by up to 18 heteroatoms. G2 and G3 independently for each occurrence represent —H, —F, —Cl, —Br, —I, —OCH3, —OCH2CH3, —OPr, —CN, —SCN, —NO, —NO2, a monovalent unsubstituted or substituted alkyl, cycloalkyl, or aryl having from 1 to 7 carbon atoms. Z and X independently for each occurrence represent —COO, —SO3, or —OPO2OR5. R5 represents a monovalent unsubstituted or substituted alkyl, cycloalkyl, or aryl having from 1 to 6 carbon atoms.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: August 6, 2019
    Assignee: SHENZHEN UNIVERSITY
    Inventors: Shiguo Chen, Lingjun Yuan
  • Patent number: 10351897
    Abstract: The present disclosure relates to acetaminophen protein adducts and methods of diagnosing acetaminophen toxicity using the acetaminophen protein adducts. The present disclosure provides acetaminophen (APAP)-protein adducts and methods of detecting acetaminophen-induced toxicity in a subject using APAP-protein adducts. One aspect of the present disclosure provides an APAP-protein adduct for diagnosing acetaminophen-induced toxicity. According to the present disclosure, the inventors have identified proteins that are modified by N-acetyl-pbenzoquinoneimine (NAPQI) in subjects with acetaminophen-induced toxicity. Non-limiting examples of proteins modified by NAPQI include betaine-homocysteine S-methyltransferase 1, cytoplasmic aspartate aminotransferase, 1,4-alpha-glucan branching enzyme, formimidoyltransferase-cyclodeaminase, and dystrophin.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: July 16, 2019
    Assignee: BioVentures, LLC
    Inventors: Laura P. James, Jack Hinson, Dean Roberts, Pritmohinder S. Gill
  • Patent number: 9862770
    Abstract: The present invention concerns methods and compositions comprising an anti-IGF-1R antibody or fragment thereof for treatment of cancer or autoimmune disease. Preferably, the cancer is renal cell carcinoma, breast cancer or pancreatic cancer. The anti-IGF-1R antibody or fragment may be part of a complex, such as a DOCK-AND-LOCK™ (DNL™) (complex produced by binding interaction between anchor domain moiety of A-kinase anchoring protein and dimerization and docking domain moiety of protein kinase A regulatory subunit) complex. Preferably, the DNL™ (complex produced by binding interaction between anchor domain moiety of A-kinase anchoring protein and dimerization and docking domain moiety of protein kinase A regulatory subunit) complex also comprises a second antibody, a second antibody fragment, an affibody or a cytokine. More preferably, the cytokine is interferon-?2b. Most preferably, the second antibody, second fragment or affibody binds to IGF-1R, TROP2 or CEACAM6.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: January 9, 2018
    Assignee: IBC Pharmaceuticals, Inc.
    Inventors: Chien-Hsing Chang, David M. Goldenberg
  • Patent number: 9795685
    Abstract: The invention relates to compounds of Formula I, wherein R1, R2, and R3 are defined in the specification, useful for the synthesis of novel conjugates and immunogens derived from aripiprazole. The invention also relates to conjugates of an aripiprazole hapten and a protein.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: October 24, 2017
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Ronghui Lin, Rhys Salter, Thomas R. DeCory, Eric Hryhorenko, Bart M. Remmerie, Banumathi Sankaran
  • Patent number: 9766196
    Abstract: An apparatus for detecting liquids or substances from liquids in spatially separate reaction zones using a plug-in module or a chip card for rapid immunological tests, for example, with the help of a reading device. The liquids or substances from liquids are detected by a sensor array and on which at least one diaphragm is arranged. Individual sensors are spatially separated from each other on a plane by means of walls. The diaphragm is filled with liquid that is to be analyzed. Sealed reaction chambers are created when pressure is applied to the diaphragm. Pores in the diaphragm are completely closed in the zone of the walls while the pores are merely reduced in size and liquid can continue to be exchanged in zones directly above the sensors. No liquid can be exchanged between adjacent reaction chambers as long as pressure is applied to and compresses the diaphragm.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: September 19, 2017
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Walter Gumbrecht, Peter Paulicka, Manfred Stanzel
  • Patent number: 9651566
    Abstract: The present invention relates to a method for determining the propensity of a fluid for calcification characterized by the following steps: (i) adding a soluble calcium salt and a soluble phosphate salt to a sample of the fluid; (ii) incubating the sample at conditions allowing the formation of calciprotein particles (CPPs); and (iii) determining one or more of the following: (a) the rate of the formation of primary and/or secondary CPPs; (b) the amount of primary and/or secondary CPPs; and/or (c) the rate of the transition of primary CPPs into secondary CPPs, wherein an increase in one or more of (a), (b) and/or (c) of step (iii) indicates an increased propensity of the fluid for calcification.
    Type: Grant
    Filed: November 7, 2012
    Date of Patent: May 16, 2017
    Assignee: Rheinisch-Westfällische Technische Hochschule Aachen
    Inventors: Wilhelm Jahnen-Dechent, Andreas Pasch, Stefan Farese, Steffen Gräber
  • Patent number: 9624233
    Abstract: The present invention includes compounds having structural formula (I), or pharmaceutically acceptable salts, solvates, and/or esters thereof. These compounds are useful for treating itch or a pruritic condition. The present invention also includes compositions comprising the present compounds and methods of treating a pruritic condition. Furthermore, the present invention provides methods for preparing the compounds.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: April 18, 2017
    Assignee: Trevi Therapeutics, Inc.
    Inventor: Amale Hawi
  • Patent number: 9465041
    Abstract: Disclosed is an antibody which binds to paliperidone, which can be used to detect paliperidone in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of paliperidone, including multiplex detection of aripiprazole, quetiapine, olanzapine, and risperidone/paliperidone in a single lateral flow assay device.
    Type: Grant
    Filed: August 20, 2013
    Date of Patent: October 11, 2016
    Assignee: Janssen Pharmaceutica NV
    Inventors: Eric Hryhorenko, Banumathi Sankaran, Thomas R. DeCory, Theresa Tubbs, Linda Colt, Maarten Vliegen, Pieter Rik Haspeslagh
  • Patent number: 9322828
    Abstract: The invention relates to monoclonal antibodies which are reactive with an epitope in the polypeptide represented by amino acid sequence 236 to 251 or 264 to 279 of the human CGA amino acid sequence. The invention further relates to the use of these monoclonal antibodies in an immunoassay for CGA, to immunoreagents comprising any of these two antibodies, and to test kits for the determination of CGA containing immunoreagents based on both of the monoclonal antibodies.
    Type: Grant
    Filed: April 28, 2011
    Date of Patent: April 26, 2016
    Assignee: Euro-Diagnostica AB
    Inventors: Mats Stridsberg, Yngve Sommarin
  • Patent number: 9322832
    Abstract: The invention provides methods for diagnosing degenerative joint disease in an animal by collecting a saliva sample from an animal; determining the amount of at least one diagnostic agent selected from the group consisting of interferon gamma, interferoninducible protein-10, interleukin-2, and total saliva protein in the saliva sample; comparing the amount of diagnostic agent found in the saliva sample to a corresponding amount of the same diagnostic agent found in a saliva sample from one or more comparable control animals that do not suffer from degenerative joint disease; and diagnosing that the animal is susceptible to or suffering from degenerative joint disease if the amount of diagnostic agent in the saliva sample from the animal is greater than the amount of same diagnostic agent found in the saliva sample from the one or more comparable control animals.
    Type: Grant
    Filed: May 8, 2012
    Date of Patent: April 26, 2016
    Assignee: Nestec S.A.
    Inventors: Steven Scott Hannah, Scott Sherrill, Qinghong Li, Peichuan Sun
  • Patent number: 9267939
    Abstract: The invention relates to compositions and methods for the immunoassay of an analyte of interest. The analyte is detected in an immunoassay using three or more antibodies, wherein each antibody specifically binds to a different epitope on the analyte. When the analyte of interest in a clinical marker for an acute disease, the detection of the analyte by immunoassay is a diagnosis of the occurrence of the disease.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: February 23, 2016
    Assignee: Abbott Point of Care Inc.
    Inventors: John Lewis Emerson Campbell, Pamela Anne Frank, Meghan Elizabeth Hawkes, Shannon Reishma Lobin, Cary James Miller, Zhen Yang
  • Patent number: 9233167
    Abstract: The invention provides compounds that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from those of the compound not attached to the water-soluble oligomer.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: January 12, 2016
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Bo-Liang Deng, Timothy A. Riley
  • Patent number: 9201077
    Abstract: Compositions, methods and kits for determining progesterone levels in mares are disclosed.
    Type: Grant
    Filed: July 27, 2010
    Date of Patent: December 1, 2015
    Assignee: Colorado State University Research Foundation
    Inventors: Terry M. Nett, Patrick M. McCue, Ryan M. Brooks, Jason E. Bruemmer, David J. Denniston
  • Patent number: 9200991
    Abstract: A sorptive extraction layer for immobilized liquid extraction of target molecules preferably from biological samples is disclosed. The sorptive extraction layer is mainly composed of ethylene-acrylate-copolymer. Preferably, microplate wells are at least partially coated with such a sorptive extraction layer. There is also disclosed a method of extracting target molecules preferably from biological samples. According to this method, immobilized liquid extraction is carried out with a sorptive extraction layer which is mainly composed of ethylene-acrylate-copolymer.
    Type: Grant
    Filed: June 4, 2013
    Date of Patent: December 1, 2015
    Assignee: TECAN TRADING AG
    Inventor: Robert Wohleb
  • Patent number: 9103839
    Abstract: The invention relates to a method of determining equine NT-proBNP, or fragments thereof, comprising the steps of: providing an equine sample, contacting the sample with at least one antibody which specifically binds to equine NT-proBNP, and determining the presence and/or concentration of the equine NT-proBNP or fragments thereof existing in the sample.
    Type: Grant
    Filed: March 7, 2008
    Date of Patent: August 11, 2015
    Assignee: BIOMEDICA MEDIZINPRODUKTE GMBH & CO KG
    Inventors: Wolfgang Woloszczuk, Gerhard Hawa
  • Publication number: 20150148249
    Abstract: The present invention discloses a method improving the sensitivity of competitive immunoassay, mainly, the small molecular substances for detection first react with the antibody/receptor sufficiently, then react with the second molecules, which locates on the solid phase and participates the competitive reactions, in a short time, which may greatly improve the sensitivity of competitive immunoassay. The present invention owns an easy operation method and a low cost, does not require expensive equipments or professional technological personnel, also, it owns a high sensitivity and adapts to a plurality of immunoassay methods.
    Type: Application
    Filed: July 4, 2013
    Publication date: May 28, 2015
    Applicant: SHENZHEN BIOEASY BIOTECHNOLOGY CO.,LTD.
    Inventors: Hai Zhu, Xiqing Li, Jinfeng Li
  • Publication number: 20150140077
    Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
    Type: Application
    Filed: January 30, 2015
    Publication date: May 21, 2015
    Applicant: SARCODE BIOSCIENCE INC.
    Inventors: Thomas Gadek, John Burnier
  • Publication number: 20150139989
    Abstract: The invention relates to antibodies directed against human Leukemia Inhibitory Factor (LIF) and to a hybridoma cell line producing said antibodies. The invention also relates to a method for blocking/inhibiting the proliferation of stem cells, and to an in vitro method for the diagnosis of diseases associated with unwanted cell proliferation in a subject or for determining the predisposition of a subject to suffer from said disease associated with unwanted cell proliferation, or for prognosis of average life expectancy of a subject suffering from said disease. The therapeutic potential of said antibodies is based on observing that the inhibition of LIF can be used in therapeutic compositions for the treatment of diseases associated with unwanted proliferation.
    Type: Application
    Filed: January 5, 2015
    Publication date: May 21, 2015
    Applicants: FUNDACIO PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÒGICA VALL D'HEBRON (VHIO), FUNDACIO PRIVADA INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS (ICREA)
    Inventors: Joan Seoane Suarez, Judit Anido Folgueira, Andrea Saez Borderias
  • Publication number: 20150140075
    Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
    Type: Application
    Filed: January 30, 2015
    Publication date: May 21, 2015
    Applicant: SARCODE BIOSCIENCE INC.
    Inventors: Thomas Gadek, John Burnier
  • Publication number: 20150132757
    Abstract: Disclosed herein is a method of detecting and identifying antigens that are shed into human bodily fluids during infection. The disclosed method allows circulating antigens associated with a particular infection to be detected within minutes or hours from testing as compared to days required with the current methods. Methods of identifying diagnostic indicators/targets for a given condition or disease are disclosed which include immunizing a verterinary subject with biological fluids obtained from a human infected with particular antigens to identify diagnostic targets for immunoassay. Also disclosed are methods of diagnosing and monitoring a B. pseudomallei-associated condition, such as melioidosis. Point-of-care immunoassays are also provided that can be used to diagnose or monitor the efficacy of a B. pseudomallei-associated condition treatment. These immunoassays can also be used for rapid diagnosis of infection produced by B. pseudomallei, such as meliodosis.
    Type: Application
    Filed: December 17, 2014
    Publication date: May 14, 2015
    Applicant: The Board of Regents of the Nevada System of Higher Education, on Behalf of the Univ. of Nevada
    Inventors: David P. AuCoin, Thomas R. Kozel, Claire Smalley
  • Publication number: 20150133337
    Abstract: Devices, systems, and methods for detecting molecules of interest within a collected sample are described herein. In certain embodiments, self-contained sample analysis systems are disclosed, which include a reusable reader component, a disposable cartridge component, and a disposable sample collection component. In some embodiments, the reader component communicates with a remote computing device for the digital transmission of test protocols and test results. In various disclosed embodiments, the systems, components, and methods are configured to identify the presence, absence, and/or quantity of particular nucleic acids, proteins, or other analytes of interest, for example, in order to test for the presence of one or more pathogens or contaminants in a sample.
    Type: Application
    Filed: January 16, 2015
    Publication date: May 14, 2015
    Inventors: Ayub Khattak, Clinton Sever
  • Patent number: 9028771
    Abstract: The invention provides a modified form of saturation assay, which is based on the measurement of a free or unbound labelled reagent fraction (such that there is an increase in signal in the presence of analyte) and employs trapping zones to concentrate said unbound or free labelled fraction to avoid loss of sensitivity. Preferably, the assay is a membrane assay.
    Type: Grant
    Filed: November 9, 2007
    Date of Patent: May 12, 2015
    Assignee: Platform Diagnostics Limited
    Inventors: Douglas Robert Evans, Gerald John Allen, Carolyn Jennifer Ruddell
  • Publication number: 20150126394
    Abstract: Methods for diagnosing cancer in a subject are disclosed. The method includes detecting the level of expression of one or more cancer markers in a biological sample obtained from the subject; and comparing the level of expression of the one or more cancer markers in the biological sample to a normal level of expression of the one or more cancer markers. The one or more cancer markers comprises CXCL13 or CXCR5 or both CXCL13 and CXCR5. Also disclosed is a kit for detecting cancer or monitoring cancer progression.
    Type: Application
    Filed: November 6, 2014
    Publication date: May 7, 2015
    Inventors: James W. LILLARD, JR., Rajesh Singh, Shailesh Singh
  • Publication number: 20150118698
    Abstract: A method of bioassay for the quantification of peptide fragments comprising a neo-epitope formed by cleavage ofmimecan, a protein of an atherosclerotic plaque, by a proteinase, said comprises contacting a sample such as urine or serum with an antibody reactive with the neo-epitope and determining the level of binding of said immunological binding partner to peptide fragments in said sample. The assay is predictive of risk of cardiovascular disease events.
    Type: Application
    Filed: May 4, 2012
    Publication date: April 30, 2015
    Applicant: Nordic Biociences A/S
    Inventors: Natas[c]ha Barascuk Michaelsen, Federica Genovese, Morten Karsdal, Diana Julie Leeming
  • Publication number: 20150111758
    Abstract: The present invention relates to compositions, kits, and methods for providing a prognosis and/or determining a treatment course of action in a subject diagnosed with breast cancer. In particular, the present invention relates to gene expression signatures useful in the prognosis, diagnosis, and treatment of breast cancer.
    Type: Application
    Filed: March 6, 2013
    Publication date: April 23, 2015
    Inventors: Therese Sorlie, Arnoldo Frigessi, Anne-Lise Borresen-Dale, Simen Myhre, Hayat Mohammed, Jens Overgaard, Jan Alsner, Trine Tramm
  • Publication number: 20150104457
    Abstract: The disclosure relates to antibodies against human IL-17 which act as antagonist antagonists of IL-17, and their use in the diagnosis or treatment of IL-17 mediated diseases.
    Type: Application
    Filed: June 25, 2013
    Publication date: April 16, 2015
    Inventors: Gilles Alberici, Jeremy Bastid, Armand Bensussan, Nathalie Bonnefoy, Jean-Francois Eliaou
  • Publication number: 20150086539
    Abstract: The subject relates to a cross-neutralizing antibody comprising at least one polyspecific binding site that binds to alpha-toxin (Hla) and at least one of the bi-component toxins of Staphylococcus aureus, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated conformational epitope recognized by a specific cross-neutralizing antibody.
    Type: Application
    Filed: April 17, 2013
    Publication date: March 26, 2015
    Inventors: Eszter Nagy, Adriana Badarau, Harald Rouha, Lukas Stulik, Gábor Nagy, Irina Mirkina, Zoltán Magyarics, Zehra Visram, Michaela Jaegerhofer, Manuel Zerbs, Ivana Dolezilkova, Astrid Teubenbacher, Michael Benjamin Battles, Bianka Dominique Prinz
  • Publication number: 20150079583
    Abstract: One aspect of the present disclosure relates to a calorimeter for detecting the presence of a target analyte in a fluid sample. The calorimeter can include a substrate, a hermetically-sealed, thermally decoupled central reaction zone associated with the substrate, at least one droplet transport region, and detection electronics. The at least one droplet transport region can be associated with the substrate and configured to merge a reagent droplet with a sample droplet including the fluid sample to form a reaction droplet in the central reaction zone. The detection electronics can be in electrical and/or thermal communication with the central reaction zone and associated with the substrate. The calorimeter can be configured to detect a heat of reaction produced by a reaction event between the target analyte and a capture reagent upon formation of the reaction droplet.
    Type: Application
    Filed: August 22, 2014
    Publication date: March 19, 2015
    Inventors: Franz Baudenbacher, Raymond Mernaugh, John Mayo, Brad Lubbers
  • Patent number: 8975087
    Abstract: Embodiments of the invention include methods for detecting and determining the concentrations of macro and small molecules, including bio-molecules, in a liquid or gaseous sample.
    Type: Grant
    Filed: November 30, 2010
    Date of Patent: March 10, 2015
    Assignee: Inanovate, Inc.
    Inventors: James Curtis Nelson, David Ure
  • Publication number: 20150065383
    Abstract: This invention provides methods and kits for improved diagnosis of medically relevant conditions by solution based biochemical testing procedures performed in solutions of test samples. The invention provides a method to substitute the cell based morphological information contained within the cytological and/or histological data of the test sample by molecular information obtainable from the solution, wherein the original test sample is dissolved and thus enables for accurate and reproducible assessment of medically relevant diagnosis from dissolved test samples. The method according to the invention comprises the steps of determining the levels of one or more disease markers associated with the condition to be diagnosed, determining the level of one or more normalization markers suitable to substitute the information related to morphological aspects of the sample, comparing and/or combining the data of the disease and normalization markers, and assessing diagnosis of a medically relevant condition.
    Type: Application
    Filed: September 8, 2014
    Publication date: March 5, 2015
    Inventors: Rüdiger RIDDER, Wolfgang Rudy, Matthias Herkert, Marcus Trunk-Gehmacher, Anja Reichert, Magnus Von Knebel Doeberitz
  • Patent number: 8969024
    Abstract: Compositions and methods comprising proteins that bind specifically to adalimumab are disclosed herein. Adalimumab is a monoclonal antibody specific for the cytokine TNF-? and was developed to treat TNF-? mediated inflammatory diseases. In one aspect of the instant invention, the binding proteins are antibodies directed toward adalimumab. These antibodies, including binding fragments thereof, can be used in a clinical setting as well as for research and development. For example, these anti-adalimumab antibodies can be employed to neutralize adalimumab.
    Type: Grant
    Filed: August 27, 2008
    Date of Patent: March 3, 2015
    Assignee: AbbVie Biotechnology Ltd
    Inventors: Zehra Kaymakcalan, Limin Xiong
  • Patent number: 8962264
    Abstract: The present invention provides a method of detecting dermatophyte, which does not require a complicated operation such as an enzyme treatment and a heat treatment. The present invention provides a method of detecting dermatophyte, including a step of extracting a dermatophyte component from a sample with a treatment liquid containing a non-ionic surfactant or a zwitterionic surfactant, and a kit for diagnosing dermatophyte infection, containing a treatment liquid comprising the above surfactant, and an antibody specifically recognizing a dermatophyte component, which are housed in separate containers.
    Type: Grant
    Filed: March 19, 2007
    Date of Patent: February 24, 2015
    Assignees: National University Corporation University of Fukui, JNC Corporation
    Inventor: Sakon Noriki
  • Patent number: 8961977
    Abstract: The present invention relates to an anti-idiotypic polypeptide scaffold that includes two or more peptide sequences that mimic a discontinuous epitope of a pathogen that is recognized by or induces formation of a broadly neutralizing antibody. Using a fibronectin FNfn10 scaffold bearing two or more modified discontinuous loops, scaffolds that recognize broadly neutralizing antibodies in vitro and from patient serum have been identified. These scaffolds should induce an immune response or mobilize germline specificities to initiate their affinity maturation.
    Type: Grant
    Filed: February 14, 2011
    Date of Patent: February 24, 2015
    Assignee: University of Rochester
    Inventors: Stephen Dewhurst, Mark A. Sullivan
  • Publication number: 20150050266
    Abstract: This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay).
    Type: Application
    Filed: December 23, 2013
    Publication date: February 19, 2015
    Applicant: Ablynx N.V.
    Inventors: Judith Baumeister, Marie-Paule Lucienne Armanda Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens, Bruno Dombrecht, Peter Schotte, Cedric Jozef Neotere Ververken, Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Tinneke Denayer
  • Patent number: 8956877
    Abstract: A separation-free assay including a binding partner, a binding partner labeled with a directly luminescent label, and a nonspecifically binding label able to affect the signal of the unbound labeled binding partner, in which a signal of the binding partner label or the signal of the nonspecific binding label is measured in a binding event, and where at least one of the binding partners is a mobile binding partner.
    Type: Grant
    Filed: August 6, 2008
    Date of Patent: February 17, 2015
    Assignee: Aqsens Oy
    Inventor: Harri Härmä
  • Patent number: 8956823
    Abstract: An anti-antibody reagent for use in a competitive or sandwich simplex or multiplex assay, said reagent comprising one or more labeled anti-antibodies for the primary antibodies to be determined in the assay, the reagent further comprising a corresponding unlabeled anti-antibody in an excess or near excess concentration with respect to their binding partners.
    Type: Grant
    Filed: August 1, 2008
    Date of Patent: February 17, 2015
    Assignee: Bio-Rad Laboratories, Inc.
    Inventors: William F. Link, Renato B. Del Rosario, Randy Sweet, David L. King
  • Publication number: 20150037823
    Abstract: The invention relates to the identification of a biomarker whose abundance in biological sample is changed in subjects with osteoarthritis and/or other ageing-related diseases. The biomarker has applications in the diagnosis of osteoarthritis and/or other ageing-related diseases, in determining the prognosis for an individual diagnosed with osteoarthritis and/or other ageing-related diseases, and in monitoring the efficacy of treatment for osteoarthritis and/or other ageing-related diseases.
    Type: Application
    Filed: June 27, 2014
    Publication date: February 5, 2015
    Inventors: Yves Henrotin, Myriam Gharbi, Michelle Deberg, Edwin De Pauw
  • Publication number: 20150037343
    Abstract: An Ang2 specific antibody, a method of inhibiting angiogenesis or a method of treating a disease related to the activation and/or overproduction of Ang2 using the antibody, and a composition for diagnosing a disease related to the activation and/or overproduction of Ang2 including the antibody.
    Type: Application
    Filed: July 30, 2014
    Publication date: February 5, 2015
    Inventors: Seok Kyun KIM, Sang Yeul Han, Kwang Hoon Lee, Kyung Eun Kim, Chung Ho Kim, Yong In Kim, Hyung-Chan Kim, Yoon Sook Lee, Hyo Seon Lee
  • Publication number: 20150037813
    Abstract: The present invention provides a means and a method for specifically measuring a substance such as a small substance with high sensitivity by a sandwich method. Specifically, the present invention provides an antibody capable of specifically binding to an affinity complex and a method of measuring of the affinity complex comprising measuring the affinity complex using the antibody capable of specifically binding to the affinity complex. The antibody of the present invention may be a full-length antibody. The antibody of the present invention may also have a region derived from an immunoglobulin from an animal having an ability of gene conversion (e.g., a complementarity-determining region, a framework region, or a variable region). Examples of at least one factor that constitutes the affinity complex include a small substance or a protein (e.g., antibody).
    Type: Application
    Filed: July 4, 2012
    Publication date: February 5, 2015
    Applicant: FUJIREBIO INC.
    Inventor: Yoshie GOISHI
  • Publication number: 20150037251
    Abstract: The invention relates inhibiting nucleic acids directed at mammalian homologues of the Drosophila fwe gene (Flower) and to antibodies against the respective proteins, and their use in diagnosing, preventing and treating cancer.
    Type: Application
    Filed: February 18, 2013
    Publication date: February 5, 2015
    Applicants: UNIVERSITAT BERN, CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS
    Inventors: Christa Rhiner, Evgeniya Pertova, Jesus M. Lopez-Gay, Eduardo Moreno
  • Publication number: 20150030603
    Abstract: An anti-Ang2 antibody or an antigen-binding fragment thereof that specifically binds to an angiogenesis-inducing factor Angiopoietin-2 (Ang2) and complexes with a Tie2 receptor and Ang2, and related methods and compositions.
    Type: Application
    Filed: July 29, 2014
    Publication date: January 29, 2015
    Inventors: Kyung Eun KIM, Seung Ja Oh, Hyo Seon Lee, Sang Yeul Han
  • Publication number: 20150031047
    Abstract: In one non-limiting aspect, the invention provides a method for detecting the quality of a biological molecule comprising forming a first mixture of ingredients comprising: (i) a first binding agent that specifically binds to a tag, wherein the first binding agent is attached to a solid support; (ii) a decoy comprising a first portion comprising the tag attached to a second portion comprising an anchor; (iii) a sensor attached to a second binding agent that specifically binds to the anchor; and (iv) a sample suspected of containing a high quality biological molecule comprising a tag, wherein the tag of the high quality biological molecule is accessible; allowing interaction of the ingredients such that the sensor provides an output signal
    Type: Application
    Filed: June 20, 2012
    Publication date: January 29, 2015
    Applicant: BioScale, Inc.
    Inventors: Edward Marshall Alderman, Brett Peter Masters, Michael Francis Miller, William Matthew Dickerson
  • Patent number: 8927225
    Abstract: Disclosed is an assay (method) to quantify the amounts of catecholamine-O-methyltransferase (COMT) protein in samples, such as extracts from cell cultures, body fluids, tissues, and environmental samples. It uses novel agents (anti-NE, COMT-NE, or COMT-epitope-NE) in combination with two previously described agents (anti-COMT and COMT) in a competitive ELISA system to achieve this aim.
    Type: Grant
    Filed: September 8, 2009
    Date of Patent: January 6, 2015
    Assignee: The University of Hong Kong
    Inventors: Shu Leong Ho, Wing Lok Ho, David Boyer Ramsden
  • Publication number: 20150004177
    Abstract: Isolated monoclonal antibodies which bind to human CD32b and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: June 27, 2014
    Publication date: January 1, 2015
    Inventors: Edward Norbert VAN DEN BRINK, Paul PARREN, Jan VAN DE WINKEL, Aran Frank LABRIJN, Frank Everhardus Martinus REBERS, Esther Cornelia Wilhelmina BREIJ
  • Publication number: 20150004634
    Abstract: Methods and assays for oversulfated glycosaminoglycans are provided. In an embodiment, the present disclosure provides a method for detecting oversulfated glycosaminoglycan (OS-GAG) in a heparin sample. The method comprises placing the heparin sample onto a support comprising immobilized heparin and contacting the heparin sample on the support with a binding compound that attaches to the heparin and forms a heparin-binding compound complex. The binding compound also has a greater affinity for attaching to the OS-GAG than to the heparin in the heparin sample and forms an OS-GAG-binding compound complex. The method can further comprise detecting an amount of the heparin-binding compound complex on the support, and determining an amount of OS-GAG in the heparin sample based on the amount of the heparin-binding compound complex on the support.
    Type: Application
    Filed: September 17, 2014
    Publication date: January 1, 2015
    Inventor: Shawn F. Bairstow
  • Publication number: 20150005192
    Abstract: The invention relates to a method of diagnosing or monitoring schizophrenia or other psychotic disorder.
    Type: Application
    Filed: September 12, 2014
    Publication date: January 1, 2015
    Applicant: Cambridge Enterprise Limited
    Inventors: Sabine Bahn, Paul Guest, Laura Harris, Yishai Levin, Divya Krishnamurthy
  • Publication number: 20140363447
    Abstract: Antibodies and fragments thereof have high affinity for human ?-synuclein protofibrils and low binding of ?-synuclein monomers, wherein the antibodies or fragments have specified Complementarity Determining Region (CDR) sequences. Compositions comprise such an antibody or fragment and methods of detecting ?-synuclein protofibrils use such an antibody or fragment. In further embodiments, methods of preventing, delaying onset of or treating a neurodegenerative disorder with ?-synuclein pathology comprise administering such an antibody or fragment, and such an antibody or fragment is used in the manufacture of a pharmaceutical composition for treatment of a neurodegenerative disorder with ?-synuclein pathology. Such an antibody or fragment is used in the diagnosis or monitoring of the development of a neurodegenerative disorder with ?-synuclein pathology, and in methods for reducing or inhibiting ?-synuclein aggregation by administration of such an antibody or fragment.
    Type: Application
    Filed: August 28, 2014
    Publication date: December 11, 2014
    Inventors: Eva Nordström, Alex Kasrayan, Monica Ekberg, Valentina Screpanti Sundquist, Lars Lannfelt, Mats Holmquist
  • Publication number: 20140363450
    Abstract: Low levels of antibodies reactive with oxidised Cardiolipin (oxCL) in mammals are related to an increased risk of developing cardiovascular diseases, auto-immune diseases or inflammatory conditions. High levels can have a protective function and in general there is a negative association between manifestations of these conditions and antibodies against oxCL. Thus, based on their relations methods of monitoring, determining and diagnosing as well as methods of immunisation and therapy of these diseases and conditions are provided.
    Type: Application
    Filed: August 12, 2013
    Publication date: December 11, 2014
    Applicant: MEDIRISTA BIOTECHNOLOGIES AB
    Inventor: Johan FROSTEGÅRD
  • Patent number: 8900882
    Abstract: In the case of assaying the level of complex AB in a sample which likely contains the complex AB composed of substance A with another substance B, the complex is assayed by the competitive homogeneous assay method with the use of reagents including a reagent containing partner C specifically binding to substance A, a reagent containing partner D specifically binding to substance B, a reagent containing fine particles carrying substance A or an analog thereof and substance B or an analog thereof, and a reagent containing partner C specifically binding to substance A and partner D specifically binding to substance B. Thus, the complex in the sample can be easily assayed. The above method is applicable to general-purpose biochemical automatic analyzers.
    Type: Grant
    Filed: May 14, 2009
    Date of Patent: December 2, 2014
    Assignees: Nitto Boseki Co., Ltd., Shinshu University
    Inventors: Kiyotaka Fujita, Ryo Kojima, Yoshiro Sato, Natsuki Sato
  • Publication number: 20140349956
    Abstract: The subject invention pertains to materials and methods for diagnosing and/or predicting pathologic infant conditions. A method of the invention comprises obtaining a biological sample from an infant and analyzing the sample to detect at least one protein biomarker of necrotizing enterocolitis (NEC), wherein a patient is diagnosed with NEC or determined to have a likelihood of developing NEC following detection of the biomarker. In another method of the invention, the likelihood of a patient developing NEC is determined. In certain embodiments, treatment is administered to the patient following diagnosis of NEC or determination that the patient has a likelihood of developing NEC.
    Type: Application
    Filed: January 16, 2013
    Publication date: November 27, 2014
    Inventor: Josef Neu